Aclaris Therapeutics Inc
aclaristx.comAclaris Therapeutics Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. The company generates no product revenue at this stage, operating instead on capital raises while advancing its pipeline toward potential partnering, licensing, or commercialization transactions with third parties. Aclaris uses its proprietary KINect drug discovery platform, which integrates small and large molecule discovery approaches, to identify product candidates designed for superior target affinity, specificity, and potency. As of the 10-K filed February 26, 2026, the company is actively seeking transactions with third-party partners to further develop, obtain regulatory approval for, and commercialize its pipeline. The business is pre-commercial, carrying the capital structure and risk profile typical of clinical-stage biotechnology companies with no approved products generating recurring revenue.
Products & Services
Novel small and large molecule product candidates targeting immuno-inflammatory diseases, discovered through the proprietary KINect drug discovery platform.
Revenue Model
No product revenue disclosed in the filing excerpts. The company is clinical-stage and pursues third-party partnering, licensing, and commercialization transactions as its path to monetization.
Customers & Markets
Patients with immuno-inflammatory diseases. No commercial customers disclosed in the filing excerpts.
Financial Snapshot
Loading...
